March 2023 in “Translational Andrology and Urology” This review discusses the pharmacology of 5-alpha reductase inhibitors, their expanding clinical indications beyond benign prostatic hyperplasia, and notes unresolved claims about their potential role in SARS-CoV-2.
108 citations
,
February 2008 in “The Journal of urology/The journal of urology” This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.
February 2020 in “Definitions” This study found that finasteride treatment may decrease contraction of seminal vesicle tissue and alter some semen parameters in male rabbits.
5 citations
,
May 2020 in “Dermatologic Therapy” This letter reports no new findings and discusses potential concerns regarding 5-alpha reductase inhibitors on lung function, suggesting a reason for discontinuation during the COVID-19 pandemic.
20 citations
,
January 2004 in “PubMed Central” This article reviews the use of 5α-reductase inhibitors for treating benign prostatic hyperplasia, suggesting potential benefits beyond symptom relief, but it reports no new clinical results.